Novel and Engineered Anti-B-Cell Monoclonal Antibodies for Non-Hodgkin's Lymphoma

Seminars in Hematology

Volumn 45, Issue 2, 2008, Pages 126-132

  Martin, Peter ^a   Furman, Richard R ^a   Ruan, Jia ^a   Elstrom, Rebecca ^a   Barrientos, Jacqueline ^a   Niesvizky, Ruben ^a   Coleman, Morton ^a   Leonard, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AME 133; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GA 101; GALIXIMAB; MONOCLONAL ANTIBODY; OFATUMUMAB; PREDNISONE; RITUXIMAB; SGN 40; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; ENGINEERING; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD22; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; LYMPHOMA, NON-HODGKIN; MICE;

EID: 41249089943     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.02.007     Document Type: Article

References (58)

1. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
2. Witzig T.E., Vukov A.M., Habermann T.M., Geyer S., Kurtin P.J., Friedenberg W.R., et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's Lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 1103-1108
3. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
4. Davis T.A., Grillo-Lopez A.J., White C.A., McLaughlin P., Czuczman M.S., Link B.K., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18 (2000) 3135-3143
5. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Ferme C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
6. Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., and Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51 (1998) 364-369
7. Thomas D.A., O'Brien S., Bueso-Ramos C., Faderl S., Keating M.J., Giles F.J., et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 102 (2003) 3906-3911
8. Li H., Ayer L.M., Lytton J., and Deans J.P. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 278 (2003) 42427-42434
9. Tedder T.F., Boyd A.W., Freedman A.S., Nadler L.M., and Schlossman S.F. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135 (1985) 973-979
10. Tedder T.F., Streuli M., Schlossman S.F., and Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 85 (1988) 208-212
11. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene. Blood 99 (2002) 754-758
12. Kim D.H., Jung H.D., Kim J.G., Lee J.-J., Yang D.-H., Park Y.H., et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108 (2006) 2720-2725
13. Cragg M.S., and Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103 (2004) 2738-2743
14. Selenko N., Majdic O., Jäger U., Sillaber C., Stöckl J., and Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. J Clin Immunol 22 (2002) 124-130
15. + cytotoxic T cells. Leukemia 15 (2001) 1619-1626
16. Theresa L.O.K., Gareth T.W., Sarah L.D., and Michael S.N. Mice carrying a CD20 gene disruption. Immunogenetics 48 (1998) 125-132
17. Alas S., and Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61 (2001) 5137-5144
18. Bannerji R., Kitada S., Flinn I.W., Pearson M., Young D., Reed J.C., et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance. J Clin Oncol 21 (2003) 1466-1471
19. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
20. Jazirehi A.R., Vega M.I., Chatterjee D., Goodglick L., and Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 64 (2004) 7117-7126
21. Mathas S., Rickers A., Bommert K., Dorken B., and Mapara M.Y. Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways. Cancer Res 60 (2000) 7170-7176
22. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., White C.A., Liles T.M., Royston I., et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 3266-3274
23. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 (1994) 2457-2466
24. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Modern Rheumatol 17 (2007) 191-197
25. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheumatism 50 (2004) 2580-2589
26. Teeling J.L., Mackus W.J.M., Wiegman L.J.J.M., van den Brakel J.H.N., Beers S.A., French R.R., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177 (2006) 362-371
27. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 (2004) 1793-1800
28. Hagenbeek A., Plesner T., Johnson P., Pedersen L., Walewski J., Hellmann A., et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts 106 (2005) 4760
29. Coiffier B., Tilly H., Pedersen L.M., Plesner T., Frederiksen H., van Oers M.H.J., et al. Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 108 (2006) 2842
30. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
31. O'Brien S.M., Kantarjian H., Thomas D.A., Giles F.J., Freireich E.J., Cortes J., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 2165-2170
32. Stein R., Qu Z., Chen S., Rosario A., Shi V., Hayes M., et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10 (2004) 2868-2878
33. Morshhauser F., Leonard J.P., Coiffier B., Petillon M., Coleman M., Bahkti A., et al. Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. ASCO Meeting Abstracts 24 (2006) 7530
34. van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., and Ebeling S.B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 12 (2006) 4027-4035
35. Shinkawa T., Nakamura K., and Yamane N. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 (2003) 3466-3473
36. Iida S., Misaka H., Inoue M., Shibata M., Nakano R., Yamane-Ohnuki N., et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to fcγRIIIa. Clin Cancer Res 12 (2006) 2879-2887
37. Niwa R., Sakurada M., Kobayashi Y., Uehara A., Matsushima K., Ueda R., et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11 (2005) 2327-2336
38. Umana P., Moessner E., Bruenker P., Unsin G., Puentener U., Suter T., et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. ASH Annual Meeting Abstracts 108 (2006) 229
39. Bowles J.A., Wang S.-Y., Link B.K., Allan B., Beuerlein G., Campbell M.-A., et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108 (2006) 2648-2654
40. Weiner G.J., Bowles J.A., Link B.K., Campbell M.A., Wooldridge J.E., and Breitmeyer J.B. Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab (R). ASH Annual Meeting Abstracts 106 (2005) 348
41. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol 17 (2005) 290-297
42. Poe J.C., Fujimoto Y., Hasegawa M., Haas K.M., Miller A.S., Sanford I.G., et al. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol 5 (2004) 1078-1087
43. Carnahan J., Wang P., Kendall R., Chen C., Hu S., Boone T., et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res 9 (2003) 3982S-3990
44. Leonard J.P., Coleman M., Ketas J.C., Chadburn A., Ely S., Furman R.R., et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 3051-3059
45. Leonard J.P., Coleman M., Ketas J.C., Chadburn A., Furman R., Schuster M.W., et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 10 (2004) 5327-5334
46. Leonard J.P., Coleman M., Ketas J., Ashe M., Fiore J.M., Furman R.R., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 5044-5051
47. Strauss S.J., Morschhauser F., Rech J., Repp R., Solal-Celigny P., Zinzani P.L., et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 24 (2006) 3880-3886
48. Younes A., and Kadin M.E. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21 (2003) 3526-3534
49. van Kooten C., and Banchereau J. CD40-CD40 ligand. J Leukoc Biol 67 (2000) 2-17
50. Advani R., Forero-Torres A., Furman R.R., Rosenblatt J.D., Younes A., Shankles B., et al. SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. ASH Annual Meeting Abstracts 108 (2006) 695
51. Chambers C.A., and Allison J.P. Costimulatory regulation of T cell function. Curr Opin Cell Biol 11 (1999) 203-210
52. Coyle A.J., and Gutierrez-Ramos J.-C. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2 (2001) 203-209
53. Dorfman D.M., Schultze J.L., Shahsafaei A., Michalak S., Gribben J.G., Freeman G.J., et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 90 (1997) 4297-4306
54. Vyth-Dreese, Boot, Dellemijn, Majoor, Oomen, Laman, et al. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 94 (1998) 580-586
55. Suvas S., Singh V., Sahdev S., Vohra H., and Agrewala J.N. Distinct role of D80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 277 (2002) 7766-7775
56. Mimori K., Kiyokawa N., Taguchi T., Suzuki T., Sekino T., Nakajima H., et al. Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells. Leukemia 17 (2003) 1164
57. Czuczman M.S., Thall A., Witzig T.E., Vose J.M., Younes A., Emmanouilides C., et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 23 (2005) 4390-4398
58. Friedberg J.W., Leonard J.P., Younes A., Fisher D.C., Gordon L.I., Moore J.O., et al. Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory, follicular NHL. ASH Annual Meeting Abstracts 106 (2005) 2435